{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:37:22Z","timestamp":1790858242805,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,2,7]],"date-time":"2011-02-07T00:00:00Z","timestamp":1297036800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1756-8722-4-6","type":"journal-article","created":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T07:15:33Z","timestamp":1297149333000},"source":"Crossref","is-referenced-by-count":109,"title":["BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance"],"prefix":"10.1186","volume":"4","author":[{"given":"Hilmar","family":"Quentmeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Eberth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Romani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarete","family":"Zaborski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans G","family":"Drexler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,7]]},"reference":[{"key":"140_CR1","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002, 346: 645-652. 10.1056\/NEJMoa011573.","journal-title":"N Engl J Med"},{"key":"140_CR2","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001, 344: 1038-1042. 10.1056\/NEJM200104053441402.","journal-title":"N Engl J Med"},{"key":"140_CR3","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001, 293: 876-880. 10.1126\/science.1062538.","journal-title":"Science"},{"key":"140_CR4","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","volume":"100","author":"C Roche-Lestienne","year":"2002","unstructured":"Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T, Fenaux P, Preudhomme C: Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 2002, 100: 1014-1018. 10.1182\/blood.V100.3.1014.","journal-title":"Blood"},{"key":"140_CR5","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas J, Wang L, Clark RE, Pirmohamed M: Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004, 104: 3739-3745. 10.1182\/blood-2003-12-4276.","journal-title":"Blood"},{"key":"140_CR6","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"FX Mahon","year":"2000","unstructured":"Mahon FX, Deininger MWN, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV: Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000, 96: 1070-1079.","journal-title":"Blood"},{"key":"140_CR7","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","volume":"95","author":"E Weisberg","year":"2000","unstructured":"Weisberg E, Griffin JD: Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines. Blood. 2000, 95: 3498-3505.","journal-title":"Blood"},{"key":"140_CR8","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","volume":"95","author":"P le Coutre","year":"2000","unstructured":"le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, Gambacorti-Passerini C: Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 2000, 95: 1758-1766.","journal-title":"Blood"},{"key":"140_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/ng1343","volume":"36","author":"Y Hu","year":"2004","unstructured":"Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Hallek M, van Etten RA, Li S: Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nature Genetics. 2004, 36: 453-461. 10.1038\/ng1343.","journal-title":"Nature Genetics"},{"key":"140_CR10","doi-asserted-by":"publisher","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","volume":"68","author":"FX Mahon","year":"2008","unstructured":"Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, Belanger C, Manley PW, Leroy C, Etienne G, Roche S, Pasquet JM: Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res. 2008, 68: 9809-9816. 10.1158\/0008-5472.CAN-08-1008.","journal-title":"Cancer Res"},{"key":"140_CR11","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/leu.2008.71","volume":"22","author":"EK Thomas","year":"2008","unstructured":"Thomas EK, Cancelas JA, Zheng Y, Williams DA: Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis. Leukemia. 2008, 22: 894-904. 10.1038\/leu.2008.71.","journal-title":"Leukemia"},{"key":"140_CR12","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","volume":"90","author":"MWN Deininger","year":"1997","unstructured":"Deininger MWN, Goldman JM, Lydon N, Melo JV: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997, 90: 3691-3698.","journal-title":"Blood"},{"key":"140_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.leukres.2009.08.031","volume":"34","author":"M Breccia","year":"2010","unstructured":"Breccia M, Alimena G: Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. Leukemia Res. 2010, 34: 129-132. 10.1016\/j.leukres.2009.08.031.","journal-title":"Leukemia Res"},{"key":"140_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.leukres.2009.10.010","volume":"34","author":"S Dovat","year":"2010","unstructured":"Dovat S, Payne KJ: Tumor suppression in T cell leukemia - the role of Ikaros. Leukemia Res. 2010, 34: 416-417. 10.1016\/j.leukres.2009.10.010.","journal-title":"Leukemia Res"},{"key":"140_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature06866","volume":"453","author":"CG Mullighan","year":"2008","unstructured":"Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui CH, Relling MV, Shurtleff SA, Downing JR: BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008, 453: 110-114. 10.1038\/nature06866.","journal-title":"Nature"},{"key":"140_CR16","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/blood-2008-08-173963","volume":"114","author":"I Iacobucci","year":"2009","unstructured":"Iacobucci I, Storlazzi CT, Cilloni D, Lonetti A, Ottaviani E, Soverini S, Astolfi A, Chiaretti S, Vitale A, Messa F, Impera L, Baldazzi C, D'Addabbo P, Papayannidis C, Lonoce A, Colarossi S, Vignetti M, Piccaluga PP, Paolini S, Russo D, Pane F, Saglio G, Baccarani M, Fo\u00e0 R, Marinelli G: Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell' Adulto Acute Leukemia Working Paty (GIMEMA AL WP). Blood. 2009, 114: 2159-2167. 10.1182\/blood-2008-08-173963.","journal-title":"Blood"},{"key":"140_CR17","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1182\/blood-2007-09-112631","volume":"112","author":"I Iacobucci","year":"2009","unstructured":"Iacobucci I, Lonetti A, Messa F, Cilloni D, Arruga F, Ottaviani E, Paolini S, Papayannidis C, Piccaluga PP, Giannoulia P, Soverini S, Amabile M, Poerio A, Saglio G, Pane F, Berton G, Baruzzi A, Vitale A, Charetti S, Perini G, Foa R, Baccrani M, Martinelli G: Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood. 2009, 112: 3847-3855. 10.1182\/blood-2007-09-112631.","journal-title":"Blood"},{"key":"140_CR18","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1038\/leu.2009.166","volume":"23","author":"A Davies","year":"2009","unstructured":"Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ, Joergensen HG, Holyoake TL, Pirmohamed M, Clark RE, Mountford JC: Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia. 2009, 23: 1999-2006. 10.1038\/leu.2009.166.","journal-title":"Leukemia"},{"key":"140_CR19","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/ng0504-440","volume":"36","author":"M Deininger","year":"2004","unstructured":"Deininger M: Src kinases in Ph+ lymphoblastic leukemia. Nature Genetics. 2004, 36: 440-441. 10.1038\/ng0504-440.","journal-title":"Nature Genetics"},{"key":"140_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/10428190701713689","volume":"49","author":"S Li","year":"2008","unstructured":"Li S: Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma. 2008, 49: 19-26. 10.1080\/10428190701713689.","journal-title":"Leuk Lymphoma"},{"key":"140_CR21","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/nrc2900","volume":"10","author":"W Kolch","year":"2010","unstructured":"Kolch W, Pitt A: Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer. 2010, 10: 618-629. 10.1038\/nrc2900.","journal-title":"Nat Rev Cancer"},{"key":"140_CR22","doi-asserted-by":"publisher","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","volume":"271","author":"RL Ilaria","year":"1996","unstructured":"Ilaria RL, Van Etten RA: P210 and P190BCR\/ABL induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996, 271: 31704-31710. 10.1074\/jbc.271.49.31704.","journal-title":"J Biol Chem"},{"key":"140_CR23","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1158\/0008-5472.CAN-04-3888","volume":"65","author":"MG Kharas","year":"2005","unstructured":"Kharas MG, Fruman DA: ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res. 2005, 65: 2047-2053. 10.1158\/0008-5472.CAN-04-3888.","journal-title":"Cancer Res"},{"key":"140_CR24","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","volume":"19","author":"A Burchert","year":"2005","unstructured":"Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, M\u00fcller-Br\u00fcsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A: Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development. Leukemia. 2005, 19: 1774-1782. 10.1038\/sj.leu.2403898.","journal-title":"Leukemia"},{"key":"140_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.molmed.2005.06.007","volume":"11","author":"DA Guertin","year":"2005","unstructured":"Guertin DA, Sabatini DM: An expanding role for mTOR in cancer. Trends Mol Med. 2005, 11: 353-361. 10.1016\/j.molmed.2005.06.007.","journal-title":"Trends Mol Med"},{"key":"140_CR26","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1096\/fj.04-1973fje","volume":"19","author":"M Mayerhofer","year":"2005","unstructured":"Mayerhofer M, Aichberger KJ, Florian S, Krauth MT, Hauswirth AW, Derdak S, Sperr WR, Esterbauer H, Wagner O, Marosi C, Pickl WF, Deininger M, Weisberg E, Druker BJ, Griffin JD, Sillaber C, Valent P: Identification of mTOR as a novel bifunctional target in chronic myeloid leukema: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J. 2005, 19: 960-962.","journal-title":"FASEB J"},{"key":"140_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1365-2362.2007.01892.x","volume":"38","author":"C Sillaber","year":"2008","unstructured":"Sillaber C, Mayerhofer M, B\u00f6hm A, Vales A, Gruze A, Aichberger KJ, Esterbauer H, Pfeilst\u00f6cker M, Sperr WR, Pickl WF, Haas OA, Valent P: Evaluation of antileukaemic effects of rapamycin in patients with imatinib resistant chronic myeloid leukaemia. Eur J Clin Inv. 2008, 38: 43-52. 10.1111\/j.1365-2362.2007.01892.x.","journal-title":"Eur J Clin Inv"},{"key":"140_CR28","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.1158\/0008-5472.CAN-07-6404","volume":"68","author":"E Menu","year":"2008","unstructured":"Menu E, Garcia J, Huang X, Di Liberto M, Toogood PL, Chen I, Vanderkerken K, Chen-Kiang S: A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33 MM myeloma model. Cancer Res. 2008, 68: 5519-5523. 10.1158\/0008-5472.CAN-07-6404.","journal-title":"Cancer Res"},{"key":"140_CR29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1158\/1535-7163.271.4.2","volume":"4","author":"D DeFeo-Jones","year":"2005","unstructured":"DeFeo-Jones D, Barnett SF, Fu S, Hancock PJ, Haskell KM, Leander KR, McAvoy E, Robinson RG, Duggan ME, Lindsley CW, Zhao Z, Huber HE, Jones RE: Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt\/PKB family members. Mol Cancer Ther. 2005, 4: 271-279.","journal-title":"Mol Cancer Ther"},{"key":"140_CR30","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrm2438","volume":"9","author":"AE Karnoub","year":"2008","unstructured":"Karnoub AE, Weinberg RA: Ras oncogenes: split personalities. Nature Rev Mol Cell Biol. 2008, 9: 517-531. 10.1038\/nrm2438.","journal-title":"Nature Rev Mol Cell Biol"},{"key":"140_CR31","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.1158\/0008-5472.CAN-10-0610","volume":"70","author":"SC Kales","year":"2010","unstructured":"Kales SC, Ryan PE, Nau MM, Lipkowitz S: Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. Cancer Res. 2010, 70: 4789-4794. 10.1158\/0008-5472.CAN-10-0610.","journal-title":"Cancer Res"},{"key":"140_CR32","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1158\/1078-0432.CCR-08-1325","volume":"15","author":"C Reindl","year":"2009","unstructured":"Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, Argiropoulos B, Mellert G, Vempati S, Duyster J, Buske C, Bohlander SK, Humphries KR, Hiddemann W, Spiekermann K: CBL exon 8\/9 mutants activate the FLT3 pathway and cluster in core binding factor\/11q deletion acute myeloid leukemia\/myelodysplastic syndrome subtypes. Clin Cancer Res. 2009, 15: 2238-2247. 10.1158\/1078-0432.CCR-08-1325.","journal-title":"Clin Cancer Res"},{"key":"140_CR33","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1038\/onc.2008.40","volume":"27","author":"S Horn","year":"2008","unstructured":"Horn S, Bergholz U, J\u00fccker M, McCubrey JA, Tr\u00fcmper L, Srocking C, B\u00e4secke J: Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells. Oncogene. 2008, 27: 4096-4106. 10.1038\/onc.2008.40.","journal-title":"Oncogene"},{"key":"140_CR34","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1126\/science.1096502","volume":"304","author":"Y Samuels","year":"2004","unstructured":"Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JKV, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE: High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004, 304: 554-10.1126\/science.1096502.","journal-title":"Science"},{"key":"140_CR35","volume-title":"Guide to Leukemia-Lymphoma Cell Lines. Braunschweig","author":"HG Drexler","year":"2010","unstructured":"Drexler HG: Guide to Leukemia-Lymphoma Cell Lines. Braunschweig. 2010, 2","edition":"2"},{"key":"140_CR36","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A Hochhaus","year":"2002","unstructured":"Hochhaus A, Kreil S, Corbin AS, La Ros\u00e9e P, M\u00fcller MC, Lahaye T, Hanfstein B, Schoch C, Cross NCP, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002, 16: 2190-2196. 10.1038\/sj.leu.2402741.","journal-title":"Leukemia"},{"key":"140_CR37","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0145-2126(99)00131-9","volume":"23","author":"CC Uphoff","year":"1999","unstructured":"Uphoff CC, Habig S, Fombonne S, Matsuo Y, Drexler HG: ABL-BCR expression in BCR-ABL-positive human leukemia cell lines. Leukemia Res. 1999, 23: 1055-1060. 10.1016\/S0145-2126(99)00131-9.","journal-title":"Leukemia Res"},{"key":"140_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1756-8722-2-3","volume":"2","author":"H Quentmeier","year":"2009","unstructured":"Quentmeier H, Schneider B, R\u00f6hrs S, Romani J, Zaborski M, MacLeod RAF, Drexler HG: SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines. J Hematol Oncol. 2009, 2: 3-10.1186\/1756-8722-2-3.","journal-title":"J Hematol Oncol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-4-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-8722-4-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-4-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T04:25:28Z","timestamp":1685939128000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-4-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,7]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["140"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-4-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,7]]},"article-number":"6"}}